C-Rad AB (publ) (CRAD-B.ST)
SEK 29.65
(1.02%)
SEK 29.65
(1.02%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 1.75 Million SEK | -56.99% |
| 2022 | 4.07 Million SEK | -36.05% |
| 2021 | 6.37 Million SEK | -14.28% |
| 2020 | 7.43 Million SEK | -63.37% |
| 2019 | 20.29 Million SEK | 0.0% |
| 2018 | - SEK | 0.0% |
| 2017 | - SEK | -100.0% |
| 2016 | 11.82 Million SEK | -7.74% |
| 2015 | 12.82 Million SEK | -23.07% |
| 2014 | 16.66 Million SEK | 44.86% |
| 2013 | 11.5 Million SEK | 23.78% |
| 2012 | 9.29 Million SEK | 9.88% |
| 2011 | 8.45 Million SEK | 31.15% |
| 2010 | 6.45 Million SEK | 35.77% |
| 2009 | 4.75 Million SEK | 36.06% |
| 2008 | 3.49 Million SEK | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q3 | - SEK | 0.0% |
| 2024 Q2 | 1.5 Million SEK | 0.0% |
| 2024 Q1 | 1.7 Million SEK | 0.0% |
| 2023 Q4 | 1.75 Million SEK | -48.44% |
| 2023 Q3 | 3.4 Million SEK | 41.67% |
| 2023 Q2 | 2.4 Million SEK | -25.0% |
| 2023 Q1 | 3.2 Million SEK | -21.49% |
| 2023 FY | 1.75 Million SEK | -56.99% |
| 2022 Q3 | 4.5 Million SEK | -15.09% |
| 2022 Q1 | 6 Million SEK | -5.87% |
| 2022 FY | 4.07 Million SEK | -36.05% |
| 2022 Q2 | 5.3 Million SEK | -11.67% |
| 2022 Q4 | 4.07 Million SEK | -9.42% |
| 2021 Q4 | 6.37 Million SEK | -10.23% |
| 2021 FY | 6.37 Million SEK | -14.28% |
| 2021 Q2 | 7.3 Million SEK | 4.29% |
| 2021 Q3 | 7.1 Million SEK | -2.74% |
| 2021 Q1 | 7 Million SEK | -5.86% |
| 2020 FY | 7.43 Million SEK | -63.37% |
| 2020 Q1 | 700 Thousand SEK | -96.55% |
| 2020 Q2 | 800 Thousand SEK | 14.29% |
| 2020 Q3 | 7.3 Million SEK | 812.5% |
| 2020 Q4 | 7.43 Million SEK | 1.86% |
| 2019 Q4 | 20.29 Million SEK | 20199.0% |
| 2019 Q2 | 12.7 Million SEK | 309.68% |
| 2019 Q1 | 3.1 Million SEK | 0.0% |
| 2019 FY | 20.29 Million SEK | 0.0% |
| 2019 Q3 | 100 Thousand SEK | -99.21% |
| 2018 Q3 | - SEK | 0.0% |
| 2018 Q2 | - SEK | 0.0% |
| 2018 Q1 | - SEK | 0.0% |
| 2018 FY | - SEK | 0.0% |
| 2018 Q4 | - SEK | 0.0% |
| 2017 Q1 | 11.8 Million SEK | -0.24% |
| 2017 Q4 | - SEK | -100.0% |
| 2017 FY | - SEK | -100.0% |
| 2017 Q3 | 300 Thousand SEK | -97.43% |
| 2017 Q2 | 11.68 Million SEK | -1.01% |
| 2016 FY | 11.82 Million SEK | -7.74% |
| 2016 Q4 | 11.82 Million SEK | 0.0% |
| 2016 Q2 | 11.71 Million SEK | 0.09% |
| 2016 Q1 | 11.7 Million SEK | -8.69% |
| 2016 Q3 | 11.82 Million SEK | 0.94% |
| 2015 Q1 | 11.75 Million SEK | -29.45% |
| 2015 FY | 12.82 Million SEK | -23.07% |
| 2015 Q4 | 12.82 Million SEK | 8.77% |
| 2015 Q3 | 11.78 Million SEK | 0.34% |
| 2015 Q2 | 11.74 Million SEK | -0.09% |
| 2014 Q3 | 11.62 Million SEK | 0.35% |
| 2014 Q4 | 16.66 Million SEK | 43.35% |
| 2014 Q1 | 11.67 Million SEK | 1.5% |
| 2014 FY | 16.66 Million SEK | 44.86% |
| 2014 Q2 | 11.58 Million SEK | -0.78% |
| 2013 Q1 | 14.54 Million SEK | 56.48% |
| 2013 Q4 | 11.5 Million SEK | -9.71% |
| 2013 FY | 11.5 Million SEK | 23.78% |
| 2013 Q2 | 12.16 Million SEK | -16.38% |
| 2013 Q3 | 12.74 Million SEK | 4.78% |
| 2012 Q4 | 9.29 Million SEK | -7.44% |
| 2012 Q3 | 10.04 Million SEK | 0.0% |
| 2012 FY | 9.29 Million SEK | 9.88% |
| 2012 Q1 | - SEK | -100.0% |
| 2012 Q2 | - SEK | 0.0% |
| 2011 Q4 | 8.45 Million SEK | 0.0% |
| 2011 FY | 8.45 Million SEK | 31.15% |
| 2011 Q1 | - SEK | -100.0% |
| 2011 Q2 | - SEK | 0.0% |
| 2011 Q3 | - SEK | 0.0% |
| 2010 FY | 6.45 Million SEK | 35.77% |
| 2010 Q3 | 9.52 Million SEK | -0.81% |
| 2010 Q1 | 8.03 Million SEK | 69.15% |
| 2010 Q2 | 9.6 Million SEK | 19.55% |
| 2010 Q4 | 6.45 Million SEK | -32.31% |
| 2009 Q4 | 4.75 Million SEK | -26.88% |
| 2009 Q2 | - SEK | -100.0% |
| 2009 Q1 | 5.42 Million SEK | 55.45% |
| 2009 FY | 4.75 Million SEK | 36.06% |
| 2009 Q3 | 6.49 Million SEK | 0.0% |
| 2008 FY | 3.49 Million SEK | 0.0% |
| 2008 Q4 | 3.49 Million SEK | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Acarix AB (publ) | - SEK | -Infinity% |
| ADDvise Group AB (publ) | 1.45 Billion SEK | 99.88% |
| ADDvise Group AB (publ) | 1.45 Billion SEK | 99.88% |
| Arcoma AB | 1.92 Million SEK | 9.03% |
| Bactiguard Holding AB (publ) | 42.3 Million SEK | 95.856% |
| BICO Group AB (publ) | 1.75 Billion SEK | 99.9% |
| Boule Diagnostics AB (publ) | 57.7 Million SEK | 96.962% |
| CellaVision AB (publ) | 28.66 Million SEK | 93.884% |
| Clinical Laserthermia Systems AB (publ) | 223 Thousand SEK | -686.099% |
| Chordate Medical Holding AB (publ) | - SEK | -Infinity% |
| Duearity AB (publ) | 2.94 Million SEK | 40.374% |
| Dignitana AB (publ) | 6.07 Million SEK | 71.154% |
| Episurf Medical AB (publ) | 2.3 Million SEK | 23.783% |
| Getinge AB (publ) | 3.9 Billion SEK | 99.955% |
| Scandinavian Real Heart AB (Publ) | 6.35 Million SEK | 72.406% |
| Iconovo AB (publ) | 4.9 Million SEK | 64.275% |
| Integrum AB (publ) | 4.84 Million SEK | 63.815% |
| Luxbright AB (publ) | 206.02 Thousand SEK | -750.872% |
| Mentice AB (publ) | 2.14 Million SEK | 18.237% |
| OssDsign AB (publ) | 214 Thousand SEK | -719.159% |
| Paxman AB (publ) | 2.53 Million SEK | 30.766% |
| Promimic AB (publ) | - SEK | -Infinity% |
| Qlife Holding AB (publ) | 3 Million SEK | 41.644% |
| SciBase Holding AB (publ) | 4.17 Million SEK | 58.052% |
| ScandiDos AB (publ) | - SEK | -Infinity% |
| Sectra AB (publ) | 19.2 Million SEK | 90.872% |
| Sedana Medical AB (publ) | 1.01 Million SEK | -73.221% |
| Senzime AB (publ) | 8.57 Million SEK | 79.564% |
| SpectraCure AB (publ) | 4.39 Million SEK | 60.132% |
| Stille AB | 38.06 Million SEK | 95.395% |
| Vitrolife AB (publ) | 1.87 Billion SEK | 99.907% |
| Xvivo Perfusion AB (publ) | 21.16 Million SEK | 91.719% |